Praxis Precision Medicines, Inc.
ulixacaltamide
essential tremor
Resolved
218days ago
Advisory committee · Dec 1, 2025
What's at stake
An FDA advisory committee reviews ulixacaltamide for essential tremor around Dec 1, 2025. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 14h ago
“Following a positive pre-NDA meeting with the FDA in December 2025,”